JP2019511570A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511570A5
JP2019511570A5 JP2018565253A JP2018565253A JP2019511570A5 JP 2019511570 A5 JP2019511570 A5 JP 2019511570A5 JP 2018565253 A JP2018565253 A JP 2018565253A JP 2018565253 A JP2018565253 A JP 2018565253A JP 2019511570 A5 JP2019511570 A5 JP 2019511570A5
Authority
JP
Japan
Prior art keywords
composition
composition according
aav
ventricle
progranulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565253A
Other languages
English (en)
Japanese (ja)
Other versions
JP7436089B2 (ja
JP2019511570A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/020397 external-priority patent/WO2017151884A1/en
Publication of JP2019511570A publication Critical patent/JP2019511570A/ja
Publication of JP2019511570A5 publication Critical patent/JP2019511570A5/ja
Priority to JP2022030769A priority Critical patent/JP7507808B2/ja
Application granted granted Critical
Publication of JP7436089B2 publication Critical patent/JP7436089B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565253A 2016-03-02 2017-03-02 前頭側頭型認知症の治療 Active JP7436089B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022030769A JP7507808B2 (ja) 2016-03-02 2022-03-01 前頭側頭型認知症の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302525P 2016-03-02 2016-03-02
US62/302,525 2016-03-02
PCT/US2017/020397 WO2017151884A1 (en) 2016-03-02 2017-03-02 Therapy for frontotemporal dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022030769A Division JP7507808B2 (ja) 2016-03-02 2022-03-01 前頭側頭型認知症の治療

Publications (3)

Publication Number Publication Date
JP2019511570A JP2019511570A (ja) 2019-04-25
JP2019511570A5 true JP2019511570A5 (cg-RX-API-DMAC7.html) 2020-03-19
JP7436089B2 JP7436089B2 (ja) 2024-02-21

Family

ID=59743281

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018565253A Active JP7436089B2 (ja) 2016-03-02 2017-03-02 前頭側頭型認知症の治療
JP2022030769A Active JP7507808B2 (ja) 2016-03-02 2022-03-01 前頭側頭型認知症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022030769A Active JP7507808B2 (ja) 2016-03-02 2022-03-01 前頭側頭型認知症の治療

Country Status (6)

Country Link
US (1) US20190328906A1 (cg-RX-API-DMAC7.html)
EP (1) EP3423109A4 (cg-RX-API-DMAC7.html)
JP (2) JP7436089B2 (cg-RX-API-DMAC7.html)
AU (1) AU2017227803B2 (cg-RX-API-DMAC7.html)
CA (1) CA3016314A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017151884A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020109343A (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CA3016314A1 (en) * 2016-03-02 2017-09-08 Julianne REIDERS Therapy for frontotemporal dementia
US20240002459A1 (en) * 2016-07-14 2024-01-04 Emory University Granulin Compositions and Uses Related Thereto
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
AU2018346104B2 (en) 2017-10-03 2023-07-27 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
KR102709597B1 (ko) 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
KR20220010062A (ko) 2017-10-03 2022-01-25 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
US20210261981A1 (en) * 2017-10-23 2021-08-26 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative diseases
AU2018375192B2 (en) * 2017-12-01 2023-11-09 Encoded Therapeutics, Inc. Engineered DNA binding proteins
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
EP3866861A4 (en) * 2018-10-16 2022-09-07 Denali Therapeutics Inc. METHODS OF TREATMENT AND MONITORING OF PROGRANULIN-ASSOCIATED DISEASES
US20220111005A1 (en) * 2019-02-01 2022-04-14 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
CA3129672A1 (en) * 2019-02-22 2020-08-27 The Trustees Of The University Of Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
FI3953377T3 (fi) 2019-04-10 2025-11-26 Prevail Therapeutics Inc Geeniterapioita lysosomaalisiin sairauksiin
EP3953378A1 (en) 2019-04-10 2022-02-16 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
GB201913974D0 (en) 2019-09-27 2019-11-13 King S College London Vector
EP4048799A4 (en) * 2019-10-22 2023-11-15 Applied Genetic Technologies Corporation ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR THE TREATMENT OF PROGRANULIN-ASSOCIATED NEURODEGENERATIVE DISEASES OR DISORDERS
EP4146797A1 (en) * 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
KR20230018378A (ko) * 2020-05-27 2023-02-07 유니버시타트 취리히 골수 세포 및 미세아교세포에서 치료 단백질을 특이적으로 발현하는 바이러스 벡터
US20230346979A1 (en) * 2020-08-10 2023-11-02 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disorders
PH12023550145A1 (en) * 2020-08-12 2024-03-18 UCB Biopharma SRL Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences
MX2023002364A (es) * 2020-08-26 2023-05-22 Univ Pennsylvania Virus adenoasociado recombinante para el tratamiento de la neurodegeneración iniciada en adultos asociada a grn.
JP2024505257A (ja) 2021-02-01 2024-02-05 レジェンクスバイオ インコーポレーテッド 神経セロイドリポフスチン症の遺伝子治療
WO2024035649A1 (en) * 2022-08-08 2024-02-15 Shape Therapeutics Inc. Compositions for progranulin expression and methods of use thereof
GB202216168D0 (en) 2022-10-31 2022-12-14 UCB Biopharma SRL Route of administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146046A2 (en) * 2006-06-07 2007-12-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
CN102006882B (zh) * 2008-01-16 2017-06-06 神经动力公司 利用颗粒体蛋白前体(pgrn)治疗神经变性疾病
LT4342992T (lt) * 2009-05-02 2025-08-25 Genzyme Corporation Genų terapija, skirta neurodegeneracinių sutrikimų gydymui
US20110203007A1 (en) * 2010-02-16 2011-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis
CA3016314A1 (en) 2016-03-02 2017-09-08 Julianne REIDERS Therapy for frontotemporal dementia

Similar Documents

Publication Publication Date Title
JP2019511570A5 (cg-RX-API-DMAC7.html)
JP2020528734A5 (cg-RX-API-DMAC7.html)
TWI878204B (zh) 腺相關病毒載體遞送肌肉特異性微小肌縮蛋白以治療肌肉萎縮症
JP2020519629A5 (cg-RX-API-DMAC7.html)
JP2018148927A5 (cg-RX-API-DMAC7.html)
JP2018508519A5 (cg-RX-API-DMAC7.html)
JP2016503405A5 (cg-RX-API-DMAC7.html)
JP2020533959A5 (cg-RX-API-DMAC7.html)
JP2020513811A5 (cg-RX-API-DMAC7.html)
JP2019513779A5 (cg-RX-API-DMAC7.html)
JP2009526067A5 (cg-RX-API-DMAC7.html)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2019537576A5 (cg-RX-API-DMAC7.html)
JP2017518271A5 (cg-RX-API-DMAC7.html)
JP2017529395A5 (cg-RX-API-DMAC7.html)
JP2017509632A5 (cg-RX-API-DMAC7.html)
TW201629225A (zh) 第九因子基因療法
IL262852B1 (en) Treatment of complement-mediated disorders
CA3025445A1 (en) Dual overlapping adeno-associated viral vector system for expressing abc4a
JP2021500352A5 (cg-RX-API-DMAC7.html)
JP2020509786A5 (cg-RX-API-DMAC7.html)
JPWO2019152609A5 (cg-RX-API-DMAC7.html)
JP2023065516A5 (cg-RX-API-DMAC7.html)
Ortolano et al. Present and future of adeno associated virus based gene therapy approaches
IL319564A (en) BAG 3 methods and uses for treating cardiac amyloidosis